Regulatory decisions made by the Food and Drug Administration (FDA) often serve as important catalysts for pharmaceutical stocks. In the following video, health-care analyst Max Macaluso discusses three upcoming FDA decisions -- on drugs developed by pharma giant Merck (MRK 0.34%), GlaxoSmithKline (GSK), and needle-free injection pioneer Antares Pharma (ATRS) -- and why investors need to keep a close watch on the outcomes of these decisions.